Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder:An integrated analysis of the complete database of multicenter placebo-controlled trials by Asherson, Philip et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1177/0269881114542453
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Asherson, P., Bushe, C., Saylor, K., Tanaka, Y., Deberdt, W., & Upadhyaya, H. (2014). Efficacy of atomoxetine
in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of
multicenter placebo-controlled trials. Journal of Psychopharmacology, 28(9), 837-846.
https://doi.org/10.1177/0269881114542453
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
Journal of Psychopharmacology
2014, Vol. 28(9) 837 –846
© The Author(s) 2014
Reprints and permissions: 
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0269881114542453
jop.sagepub.com
Background
Attention deficit hyperactivity disorder (ADHD) is a common 
neurodevelopmental disorder of childhood, with an estimated 
average prevalence of 5% in different geographical regions 
(Polanczyk et al., 2010). Follow-up studies of children with 
ADHD show persistence of ADHD into adulthood in approxi-
mately 29% of the cases based on meeting the same diagnostic 
criteria as ADHD in childhood (Barbaresi et al., 2013), or even 
higher proportions when evaluating the persistence of some of 
the ADHD symptoms, which still cause significant levels of psy-
chosocial impairment (Faraone et al., 2006). A cross-national 
study using data collected across the Americas, Europe, and Asia 
estimated a prevalence in adults of 3.4% based on the Diagnostic 
Interview Schedule of the Diagnostic and Statistical Manual of 
Mental Illness, 4th Edition (DSM-IV) (Fayyad et al., 2007). 
These data are consistent with persistence rates estimated from 
clinical follow-up studies and reported in other surveys and 
meta-analytic reviews (Kessler et al., 2006; Simon et al., 2009).
Persistence of ADHD into adulthood is associated with a wide 
range of outcomes and levels of impairment (Asherson et al., 
2012). When severe, the condition can be disabling: however, 
even moderate levels of impairment can be distressing to indi-
viduals and cause significant functional impairment in their daily 
lives. This is due at least in part to the chronicity of ADHD and its 
association with the development of comorbid mental health and 
behavioral problems (Biederman et al., 1993). For example, a 
Norwegian study found that ADHD in adults was associated with 
lower educational achievement and levels of employment, result-
ing in fewer ADHD subjects having employment as their income 
source; with subsequent consequences for society in general 
(Gjervan et al., 2012).  In addition, ADHD is particularly common 
among individuals with severe comorbid disorders, including 
autism, antisocial and borderline personality disorders, addiction 
disorders, and bipolar disorder (Kooij et al., 2010; Skirrow et al., 
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Abstract
Persistence of attention deficit hyperactivity disorder (ADHD) into adulthood can be disabling or lead to substantial impairment. Several clinical trials of 
atomoxetine (ATX) in adults with ADHD have been reported following the National Institute for Health and Clinical Excellence (NICE) guidelines issued 
in 2008. We performed an integrated analysis of all Eli Lilly-sponsored, randomized, double-blind, placebo-controlled studies of ATX in adults with ADHD 
completed as of May 2012. Individual patient data were pooled from six short-term (10–16 week) studies (1961 patients) and three longer-term (six-
month) studies (1413 patients). In the short-term analysis, ATX patients achieved a significantly greater mean reduction in ADHD symptoms than placebo 
patients (−12.2 vs −8.1; Conners’ Adult ADHD Rating Scale–Investigator-Rated: Screening Version (CAARS-Inv: SV); p<0.001). In the longer-term analysis, 
respective improvements after six months were −13.2 vs −9.7 (p<0.001). Response rates at study endpoints for ATX vs placebo, based on CAARS-Inv: SV 
improvement ≥30% and Clinical Global Impressions of ADHD-Severity (CGI-ADHD-S) ≤3 were 34.8% vs 22.3% in the short-term and 43.4% vs 28.0% after 
six months, and CAARS-Inv: SV improvements ≥40% were 41.3% vs 25.3% in the short-term and 44.0% vs 31.4% after six months (all p<0.001). Overall, 
ATX had a clinically significant effect in adults with ADHD, with reductions in core symptoms and clinically meaningful responder rates.
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2012). A recent very large epidemiological survey of ADHD in 
Sweden found rates of criminal convictions around four times the 
general population rate, with reductions in convictions linked to 
prescribing of medical treatments, both stimulant and non-stimu-
lant medications (Lichtenstein et al., 2012).
Access to clinical resources for ADHD in adults remains lim-
ited in many countries, in part because of the traditional perspec-
tive that ADHD is a problem restricted to childhood and due to 
the lack of approved treatments in many countries (Kooij et al., 
2010). However, awareness of ADHD in adults is growing rap-
idly and there is now an urgent need to broaden understanding of 
the condition and to evaluate the effectiveness of available thera-
peutic interventions.
Based on current evidence, national and international guide-
lines recommend drug treatments as the first-line of clinical man-
agement for ADHD in adults, particularly where the disorder is 
associated with moderate-to-severe levels of impairment 
(Canadian Attention Deficit Hyperactivity Disorder Resource 
Alliance (CADDRA), 2011; Kooij et al., 2010; National Institute 
for Health and Clinical Excellence (NICE), 2008; Nutt et al., 
2007). In the USA a wide range of pharmacological treatments 
are approved for use in adults, including atomoxetine (ATX), 
methylphenidate (MPH), dexmethylphenidate, and various 
amphetamines (Castells et al., 2011; Fredriksen et al., 2013). 
ATX was approved in the EU in May 2013 for initiation in adults 
to treat ADHD. No other medications are approved in Europe to 
be initiated for treatment of ADHD in adults, except in Germany 
only, where a long-acting form of MPH is approved since 2011.
ATX has been approved for use in children and adults in the 
USA since 2002 and for use in children and adolescents, as well 
as continuation of treatment into adulthood in Europe since 2004. 
ATX is a non-stimulant selective noradrenalin reuptake inhibitor 
(Bymaster et al., 2002). The onset of the effects of ATX on 
ADHD is gradual in children and adolescents and may take up to 
at least 12 weeks to be fully established (Montoya et al., 2009). 
Common side effects include typical noradrenergic side effects 
(nausea, dry mouth, sweating), and possible increases in heart 
rate and blood pressure. ATX appears to have low abuse-poten-
tial. In human laboratory studies, clinical trials and clinical prac-
tice, there is no evidence that ATX induces any subjective effects 
indicative of abuse (Upadhyaya et al, 2013).
In this manuscript, we report on a systematic review and inte-
grated analysis of all available double-blinded randomized pla-
cebo-controlled studies of ATX in adults with ADHD. An 
integrated efficacy analysis is a patient-level meta-analysis where 
complete individual level data are combined across study data-
sets, obviating the need to amalgamate summary results from 
publications of individual studies, as in standard meta-analyses. 
In this integrated statistical analysis the complete set of rand-
omized placebo-controlled studies conducted by Eli Lilly and 
Co. are included. We set out to summarize findings from all stud-
ies of ATX in adults with ADHD, including those that were not 
available when previous guidelines and reviews were published. 
Randomized double-blinded placebo-controlled studies from 
other groups have not been published, so we present an analysis 
of all potential data that could be included in this study at this 
time. One particular focus is on the results of longer-term studies 
which lasted for six months.
The systematic review includes all published studies and 
reports results using an integrated efficacy analysis of all nine 
randomized, placebo-controlled studies with ATX in adults 
with ADHD. These studies were submitted and assessed by the 
European Union (EU) authorities for demonstration of efficacy 
and safety. The overall aim was to provide the first integrated 
analysis of the efficacy of ATX in adults with ADHD based on 
currently available data, particularly regarding long-term use, 
including clinically meaningful responder rates and effect size 
calculations, thus allowing indirect comparisons with other 
medications. The safety data from a related integrated dataset 
are reported in a separate publication (Camporeale et al., 2014).
Methods
An integrated (pooled) analysis was performed. An integrated 
analysis can be viewed as a meta-analysis of individual patient-
level data, as opposed to study-level summary data used in meta-
analyses. This allows patient characteristics to be investigated by 
within-subgroup analyses which were not part of the original 
study analyses. The present analysis included all multicenter, 
randomized, double-blind efficacy studies of ATX in adults spon-
sored by Eli Lilly. Two Eli Lilly-sponsored studies were not 
included in the integrated analysis: one phase 2 cross-over study 
with very short treatment periods of three weeks (Spencer et al., 
1998) and a maintenance of effect study including a randomized 
withdrawal period of atomoxetine responders (Upadhyaya et al., 
2013) were not included as these had different objectives and 
study designs.  The included studies comprised six short-term 
(10–16 week) placebo-controlled studies, including two studies 
of ADHD with comorbid disorders, and three longer-term (six-
month) placebo-controlled studies (Table 1). In Table 1, and 
throughout this paper, each source study is referred to using their 
alphabetically-assigned Eli Lilly study identifier. New analyses 
were undertaken to calculate response rates across studies based 
on common definitions of response.
Data from the nine included studies were pooled to provide 
more precise estimates of response and responder rates, and 
effect size, and to increase the power of the analysis relative to 
the smaller subpopulations in the individual studies. All included 
studies were similar regarding inclusion criteria based on 
DSM-IV diagnostic criteria for ADHD and the use of the Connors 
Adult ADHD Diagnostic Interview from DSM-IV (CAADID) to 
establish the clinical diagnosis. Table 1 provides an overview of 
the designs of the included studies.
Regarding the acute studies of adults with ADHD, patients in 
one study (Eli Lilly study identifier: LYBY) had comorbid alco-
hol abuse (Wilens et al., 2011) and patients in another study (Eli 
Lilly study identifier: LYDQ) had comorbid social anxiety disor-
ders (Adler et al., 2009a).  Other Axis I comorbidities were 
excluded from all studies.
The choice of rating scales was not identical in all studies. 
The use of specific scales in specific studies is shown in Table 1. 
The following efficacy measures were assessed in the integrated 
analysis: (a) standard core symptom rating scales for ADHD in 
adults, based on DSM-IV items; (b) functional outcome meas-
ures; and (c) clinical response, defined as a combination of 
improvements in both core symptoms and functional response.
Core symptoms
The CAARS-Inv: SV (Conners’ Adult ADHD Rating Scale-
Investigator Rated: Screening Version) was administered in eight 
out of the nine studies. The total CAARS score was the primary 
efficacy measure in seven of the nine studies. The CAARS-Inv: SV 
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(Conners et al., 1999) is a 30-item scale containing three subscales: 
inattention, hyperactivity-impulsivity, and the ADHD index.
The AISRS (Adult ADHD Investigator Symptoms Rating 
Scale) was administered as the primary efficacy measure in two 
studies (LYBY, LYCU). It is an 18-item scale that captures the 18 
DSM-IV symptoms of ADHD (Spencer et al., 2010).
Functional outcome measures
CGI-ADHD-S (Clinical Global Impression-Severity) or CGI 
overall. The CGI scale is a standardized assessment measure. It 
provides a general rating of a patient’s overall impairment or 
overall improvement (Guy, 1976). The versions used in the stud-
ies reported were the CGI-ADHD-S, which consists of a single-
item rating of the clinician’s assessment of the severity of ADHD 
symptoms in relation to the clinician’s total experience with 
ADHD patients and the CGI-Overall-S, which is a modified ver-
sion of the CGI used in the studies that included patients with 
ADHD and comorbid disorders (LYBY and LYDQ).
The Adult ADHD Quality-of-Life Scale (AAQoL) is a 
29-item patient-reported outcome measure used to examine dis-
ease-specific functional impairments relevant to adults with 
ADHD (Brod et al., 2006). The five AAQoL subscales cover life 
productivity, psychological health, life outlook, and relation-
ships. The AAQoL was administered in five of the nine studies.
Response measures
Response measures based on the CAARS and CGI were primary 
or secondary endpoints in five of the nine adult studies using 
either a priori defined response criteria at certain time points 
(four studies) or a time to response analysis (two longer-term 
Table 1. Design characteristics of placebo-controlled studies of atomoxetine in adult patients with attention deficit hyperactivity disorder (ADHD).
Eli Lilly study 
identifier
Age (mean), years Male/female Duration of 
double-blind 
treatment, weeks
ATX doses (mg/day) 
and sample size
Location of sites Disorder Primary measure Key secondary 
measure(s)
Short-term studies
LYAA ≥18 (40.3) 178/102 10 60–120 b.i.d. USA, Canada ADHD CAARS-Inv: SV CGI-ADHD-S
ATX n=141
Placebo n=139
LYAO ≥18 (42.1) 170/86 10 60–120 b.i.d. USA ADHD CAARS-Inv: SV CGI-ADHD-S
ATX n=129
Placebo n=127
LYEE ≥18 (32.3) 185/203 10 40–120 q.d. Japan, South 
Korea, Taiwan
ADHD CAARS-Inv: SV BRIEF-A, EQ-5D, 
AAQoL, CGI-
ADHD-S
ATX n=195
Placebo n=196
LYBY ≥18 (34.6) 125/22 12 25–100 q.d. or b.i.d. USA, Canada ADHD with 
alcohol abuse
AISRS, Time to 
relapse of alcohol 
abuse
CGI-Overall-S
ATX n=72
Placebo n=75
LYDQ 18–65 (38.0) 237/205 16 40–100 b.i.d. USA ADHD with 
social anxiety 
disorder
CAARS-Inv: SV LSAS, CGI-Overall-
S, AAQoLATX n=224
Placebo n=218
LYDZ 18–30 (24.7) 255/190 12 40–100 b.i.d. USA and Puerto 
Rico
ADHD CAARS-Inv: SV CGI-ADHD-S, 
AAQoL, BRIEF-AATX n=220
Placebo n=225
Longer-term studies
LYCW ≥18 (41.3) 239/263 26 40–100 o.m. USA ADHD CAARS-Inv: SV CGI-ADHD-S, 
FAM-IIIATX n=268
Placebo n=234
LYBV 18–50 (36.8) 240/170 26 40–100 q.d. (but 
b.i.d. allowed)
USA ADHD EWPS CGI-ADHD-S, 
CAARS-Inv: SV, 
AAQoLATX n=271
Placebo n=139
LYCU 18–54 (37.6) 254/247 26 25–100 o.m. USA ADHD AISRS CGI-ADHD-S, 
CAARS-Inv: 
SV, CAARS-O: 
SV-evening; 
ASRS Symptom 
Checklist Evening, 
Brown ADD, STAI, 
D-KEFS, AAQoL
ATX n=250
Placebo n=251
AAQoL: Adult ADHD Quality-of-Life Scale; ADHD: attention deficit hyperactivity disorder; AISRS: Adult ADHD Investigator Symptoms Rating Scale; ASRS: Adult ADHD Self-
Report Scale Symptom Checklist; ATX: atomoxetine; b.i.d.: twice daily; BRIEF-A: Behavior Rating Inventory of Executive Functioning–Adult version; Brown ADD: Brown 
Attention Deficit Disorder Scale; CAARS-Inv: SV: Conners’ Adult ADHD Rating Scale–Investigator-Rated; CAARS-O: SV: CAARS–Observer-Rated; CAARS-S: SV: CAARS– 
Self-Rated; CGI-ADHD-S: Clinical Global Impressions of ADHD-Severity; CGI-Overall-S: Clinical Global Impressions Overall-Severity; DB: double-blind; D-KEFS: Delis-Kaplan 
Executive Functioning System; DSM-IV: Diagnostic and Statistical Manual of Mental Illness, 4th Edition; EQ-5D: EuroQol: 5 Dimensions Questionnaire; EWPS: Endicott Work 
Productivity Scale; FAM-III: Dyadic Relationship Scale of the Family Assessment Measure, version 3; LSAS: Liebowitz Social Anxiety Scale; n: number of patients; o.m.: 
every morning; q.d.: every day; STAI: State Trait Anxiety Inventory.
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studies). In this integrated analysis we used three response defini-
tions based on CAARS and CGI. Symptomatic response was 
assessed by CAARS-Inv: SV Total score improvement with three 
different levels of decrease, ≥30%, ≥40%, and ≥50% from base-
line to endpoints. A combined symptomatological and functional 
response definition evaluated responses based on functional 
improvement only; specifically a CGI-ADHD-S score improved 
to less than or equal to three (i.e. at most mildly ill) at study end-
point. In addition response regarding quality of life was assessed 
by an AAQoL improvement of ≥1 SD at baseline. Responder 
rates were calculated separately for the short-term and the longer-
term studies.
Statistical methods for integrated analysis
For the analysis of continuous measures, an analysis of variance 
(ANOVA) model which contained the main effects of treatment 
and trial was used for demographics analysis. An analysis of 
covariance (ANCOVA) model was used with the terms in the 
ANOVA with baseline added as a covariate. The last observation 
carried forward (LOCF) method was used for missing data in the 
efficacy analyses.
For subgroup analysis of the CAARS-Inv-SV, an ANCOVA 
model which contained baseline, trial, treatment, subgroup and 
the treatment-by-subgroup interaction was used. For categorical 
data, the significance of overall treatment group differences was 
assessed using Fisher’s exact test for demographics analysis, and 
Cochran-Mantel-Haenszel statistic stratified by study for effi-
cacy analysis.
Results
Individual studies
The main efficacy results from six short-term and three longer-
term (six-month) placebo-controlled studies, which were 
included in the integrated analyses, are summarized in Tables 
2(a) and 2(b), respectively.
Integrated analyses of baseline 
characteristics
In total, 1961 patients (from the six short-term studies) and 1413 
patients (from the three longer-term studies) were included in the 
integrated efficacy analyses. All patients were adults who had a 
diagnosis of ADHD according to DSM-IV criteria and did not 
have concomitant depression or bipolar disorder. Table 3 presents 
an overview of the patient demographics and baseline character-
istics by treatment. In the short and longer-term integrated analy-
ses, no statistically significant differences were observed between 
ATX and placebo treatment groups with age, sex or ethnicity. In 
all nine studies combined, 55.8% of the patients were male, 
73.5% Caucasian, and most (~90%) were recruited in the US and 
Canada.
Integrated analyses
As described below, in the pooled analyses ATX demonstrated 
statistically significantly greater mean improvements than 
placebo in measures of ADHD symptomatology, functioning and 
responder rates (Tables 4 and 5).
Short-term studies. In the pooled analyses, based on the five 
out of six short-term studies that used the CAARS-Inv: SV Total 
score, ATX-treated patients achieved statistically significantly 
greater mean reduction in ADHD symptoms compared with pla-
cebo-treated patients (−12.4 vs −8.4) and, as presented in Table 4, 
in the CAARS-Inv: SV inattention and hyperactivity-impulsivity 
subscales (−6.9 vs −4.7 and −5.5 vs −3.7, respectively), with 
p<0.001 for all three measures. The CGI-ADHD-S, the key func-
tional outcome measure in four of the studies, showed statisti-
cally significantly greater mean improvement in ATX-treated 
compared with placebo-treated patients (−1.0 vs −0.6; p<0.001; 
Table 4). The average effect size for ATX compared with placebo 
at 10 weeks (based on CAARS-Inv: SV Total score) was 0.41 for 
the integrated short-term analysis.
In the responder analyses, based on CAARS and CGI-
ADHD-S, five response definitions were analyzed and are pre-
sented in Table 5. ATX-treated patients had statistically 
significantly higher response rates compared with placebo-
treated patients for all three cutoffs (≥30%, ≥40%, ≥50%) in the 
symptomatic response definition based on the CAARS-Inv: SV 
Total score, as well as in the combined response criterion based 
on CAARS-Inv: SV Total score and the CGI-ADHD-S.
As an additional functional outcome measure analysis, the 
AAQoL total score and subscores were available in three of the 
studies. ATX-treated patients achieved statistically significantly 
greater mean improvement than placebo-treated patients in the 
AAQoL total score (13.7 vs 9.7; p<0.001) and all of the sub-
scores (life productivity, p<0.001; psychological health, p= 
0.001; life outlook, p=0.003; and relationships, p<0.001; Table 
4).  A response based on quality of life measurements showed a 
statistically significant difference between ATX and placebo-
treated patients at the endpoints of the short-term studies 
(p=0.002; Table 5).
To determine differential effects, a subgroup analysis based 
on the mean change from baseline to endpoint on the CAARS-
Inv: SV Total score was performed using data from the short-
term studies integrated analysis. Subgroups analyzed were age 
group, ethnicity, sex, CYP2D6 status, prior stimulant use, base-
line ADHD severity, baseline quality-of-life, and ADHD sub-
type.  Of these, the only analysis that demonstrated a statistically 
significant treatment-by-subgroup interaction was ethnicity 
(p=0.027). This result was driven by much higher placebo 
responses in the small (n=235, 7.0%) group of Hispanics relative 
to other groups.
Longer-term studies. In the longer-term pooled analysis, ATX-
treated patients achieved statistically significantly greater mean 
reductions in ADHD symptoms compared with placebo-treated 
patients in the CAARS-Inv: SV Total score (−13.2 vs −9.7) and 
the Inattention and Hyperactivity-Impulsivity subscales (−7.5 vs 
−5.4 and −5.7 vs −4.3, respectively), with p<0.001 for all three 
measures (Table 4).
ATX-treated patients also achieved statistically significantly 
greater mean improvement than placebo-treated patients in CGI-
ADHD-S (−1.1 vs −0.8; p<0.001; Table 4). The average effect 
size for ATX compared with placebo after six months was 0.31 
for the integrated longer-term analysis.
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Table 2(b). Efficacy data from individual longer-term (six-month), placebo-controlled studies: changes by treatment group from baseline.
Eli Lilly study identifier LYBV LYCU LYCW
 Placebo vs ATX (p-value) Placebo vs ATX (p-value) Placebo vs ATX (p-value)
Number of patients 109 vs 185 216 vs 214 234 vs 268
Completion rates (%) 38.4 vs 48.9 37.6 vs 44.6 44.4 vs 57.3
CAARS-Inv: SV, mean change from baselinea  
Total score
−11.5 vs −11.6 (0.412)b −10.2 vs −13.2 (0.005)c −8.3 vs −14.3 (<0.001)d
Inattention subscore −6.7 vs −6.9 (0.406) −5.7 vs −7.4 (0.013) −4.4 vs −8.1 (<0.001)
Hyperactive/impulsive subscore −4.8 vs −4.7 (0.538) −4.6 vs −5.8 (0.006) −3.9 vs −6.2 (<0.001)
AAQoL, total score 11.18 vs 13.90 (0.045) 8.62 vs 13.14 (0.004) Scale not used
CGI-ADHD-S, mean change from baseline −0.9 vs −1.0 (0.173) −0.9 vs −1.2 (0.001) −0.7 vs −1.2 (<0.001)
Response rate (%)e 33.9 vs 41.1 (0.165) 29.2 vs 41.6 (0.006) 24.2 vs 46.6 (<0.001)
Mean time to response (days) Not analyzed 84 vs 53 (<0.001) 61 vs 40 (<0.001)
Remission rate (CGI-S 1 or 2) Not analyzed Not analyzed 12.1 vs 20.8 (0.011)
Mean time to remission (days) Not analyzed 142 vs 165 (0.001) 144 vs 125 (<0.001)
Reference Adler et al., 2008 Adler et al., 2009b Young et al., 2011
AAQoL: Adult ADHD Quality-of-Life scale; ATX: atomoxetine; CAARS: Connors Adult ADHD Rating Scale; CGI-ADHD-S: Clinical Global Impression of Severity for ADHD.
aMean changes in CAARS-Inv: SV were calculated using the LOCF method.
bThe primary measure for Study LYBV was Endicott Work Productivity Scale (EWPS), used to evaluate work productivity.
cThe primary measure for Study LYCU was a repeated measures analysis of the Adult ADHD Investigator Symptom Rating Scale (AISRS), which showed similar results 
(−11.7 for placebo vs −16.2 for ATX; p=0.001) to the CAARS-Inv: SV.
dThe primary analysis for Study LYCW was a repeated measures analysis, which showed similar results (−8.7 for placebo vs -16.4 for ATX; p<0.001) to the CAARS-Inv: SV.
eResponse was defined as a ≥30% CAARS-Inv: SV improvement and CGI-ADHD-S ≤3.
In the responder analyses based on CAARS and CGI, five 
response definitions were analyzed in a similar way as in the 
short-term pooled analysis (Table 5). ATX patients had statisti-
cally significantly higher response rates compared with placebo 
patients for all three cutoffs (≥30%, ≥40%, ≥50%) in the sympto-
matic response definition based on the CAARS-Inv: SV Total 
score. In a stringent combined symptomatological and functional 
response criterion using a definition of ≥30% reduction in 
CAARS-Inv: SV total score and a CGI-ADHD-S score ≤3, the 
proportion of ATX responders at six months was significantly 
larger than for placebo (43.4% vs 28.0%; p<0.001, Table 5).
The AAQoL was used to assess quality-of-life and additional 
functional outcomes in two of the three longer-term studies 
(LYBV and LYCU). In the pooled analysis of AAQoL total and 
subscores for these two studies, ATX-treated patients achieved 
statistically significantly greater mean improvement than pla-
cebo-treated patients in AAQoL total score (13.5 vs 9.6; p=0.001) 
and three of the four subscores (life productivity, p=0.001; psy-
chological health, p=0.021; and life outlook, p=0.003; Table 4). 
An analysis based on the AAQoL showed a statistically signifi-
cant higher quality of life responder rate for ATX compared to 
placebo-treated patients at the endpoint of the longer-term stud-
ies (see Table 5).
Discussion
In this integrated analysis, we were able to assess not only core 
ADHD symptom change but also functional and clinically mean-
ingful responder rates, based on all nine placebo-controlled ATX 
trials undertaken in adults by Eli Lilly. There are currently no 
published direct comparative trials of ATX with stimulants or 
other targeted treatments for adults with ADHD. Hence, the 
response rates and effect sizes that we calculated in this 
integrated analysis only allowed indirect comparisons with data 
available for other treatments. Nevertheless, our findings may 
have relevance for clinicians, guideline development and future 
trial design.
In both the short-term and longer-term analyses, ATX demon-
strated clinical efficacy versus placebo in all variables including 
response rates and effect size.
Across all six short-term studies and in the short-term inte-
grated analysis, ATX demonstrated significantly greater mean 
improvement than placebo on core measures of ADHD symp-
toms, quality-of-life and functional impairment. In a majority of 
the analyses of clinically meaningful response, as defined using 
measures of symptoms, measures of functional impairment, or a 
combination of both, there were significantly higher proportions 
of ATX-treated patients achieving a positive outcome compared 
with placebo. The consistency of these results across all six short-
term studies demonstrates that ATX has a robust effect improving 
ADHD symptomatology and functional outcomes in the short-
term treatment of adult patients with ADHD.
Although no head-to-head comparative studies of ATX and 
stimulants are available, results were recently reported in a study 
which used ATX and MPH as active comparators vs placebo and 
bavisant, a histamine H3 receptor agonist (Weisler et al., 2012). 
ATX and long-acting MPH were both statistically significantly 
superior to placebo after six weeks of treatment and showed com-
parable mean improvements based on the ADHD-RS scale from 
baseline of −15.3 for ATX and −15.7 for long-acting MPH (Weisler 
et al., 2012). Overall our results suggest that effect sizes are more 
similar to those of stimulants than previously thought, with recent 
meta-analyses of MPH in adults with ADHD giving average effect 
sizes around 0.5 (Castells et al., 2011; Koesters et al., 2009).
As ADHD in adults is usually treated over long periods, 
longer-term studies evaluating efficacy are of particular value. 
Regarding the use of ATX in children, there is evidence that the 
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Table 3. Demographics and baseline characteristics of patients in the short-term and longer-term studies (integrated analyses).
Parameter Short-term studies integrated analysis Longer-term studies integrated analysis
Placebo ATX p-value Placebo ATX p-value
Age (years), N 980 981 624 789  
Mean±SD 34.2±11.1 34.8±11.3 0.39 38.6±9.0 38.7±8.8 0.48
Sex, N 980 981 624 789  
Male, n (%) 575 (58.7) 575 (58.6) 1.00 320 (51.3) 413 (52.3) 0.71
Female 405 (41.3) 406 (41.4) 304 (48.7) 376 (47.7)  
Ethnic origin, N 980 981 624 789  
White, n (%) 632 (64.5) 646 (65.9) 0.61 531 (85.0) 671 (85.0) 0.90
Black 53 (5.4) 46 (4.7) 32 (5.1) 37 (4.7)  
Asian 214 (21.8) 216 (22.0) 6 (1.0) 9 (1.1)  
Hispanic 69 (7.0) 67 (6.8) 45 (7.2) 54 (6.8)  
Other 12 (1.2) 6 (0.6) 10 (1.6) 18 (2.3)  
ADHD subtype, N 980 979 623 789  
Inattentive, n (%) 331 (33.8) 325 (33.2) 0.73 177 (28.4) 239 (30.3) 0.72
Hyperactive/impulsive 18 (1.8) 14 (1.4) 5 (0.8) 5 (0.6)  
Combined 631 (64.4) 640 (65.4) 441 (70.8) 545 (69.1)  
CAARS-Inv: SV scores, N 905 909 623 786  
Mean±SD 35.3±8.1 35.1±8.2 0.55 35.8 ±8.3 35.0±8.2 0.11
CGI-ADHD-S scores, N 687 685 624 789  
Mean±SD 4.7±0.7 4.8±0.7 0.30 4.6±0.6 4.6±0.7 0.42
<4, n (%) 0 (0.0) 0 (0.0) 0.18 0 (0.0) 1 (0.1) 0.26
4–5 591 (86.0) 571 (83.4) 579 (92.8) 717 (90.9)  
>5 96 (14.0) 114 (16.6) 45 (7.2) 71 (9.0)  
ATX: atomoxetine; CAARS-Inv: SV: Conners’ Adult ADHD Rating Scale–Investigator-Rated; CGI-ADHD-S: Clinical Global Impressions of ADHD-Severity; N: number of ran-
domized patients per parameter; n: number of patients per sub-parameter; SD: standard deviation.
Studies LYBY and LYDQ are excluded from CGI-ADHD-S descriptive statistics because they were conducted in comorbid populations. Similarly, Study LYBY did not collect 
CAARS-Inv: SV, therefore the numbers of patients included in the analyses are lower than the numbers randomized, p-values for categorical data are from Fisher’s exact 
test; p-values for ethnicity are from the chi-square test; p-values for continuous data are from the Type III sums of squares analysis of variance (ANOVA) model with 
terms for treatment and study.
response of ADHD symptoms increases with time on medication, 
with results suggesting further improvement in effect size up to 
12 weeks (Bushe and Savill, 2011). A similar result was seen in 
Study LYCU, with maximum effect size around 10 weeks, fol-
lowed by a stable effect up to six months (Adler et al., 2009b). In 
the other positive long-term study, further enhancement of the 
effect size was seen beyond 12 weeks, with effect size increasing 
from 0.41 at 12 weeks to 0.57 at six months (Young et al., 2011). 
These two studies show statistically significant but not maximal 
treatment effects at 2–4 weeks, which was also seen in other ATX 
studies (Durell et al., 2013; Michelson et al., 2003).
Despite the finding in the Young et al. study (2011) of a maxi-
mal effect at six months, an enhanced effect size developing 
beyond three months is not seen in the overall findings from the 
integrated analysis; comparing the average effect size of the 
short-term studies (0.41) to the longer-term studies (0.31). 
However, there are limitations to drawing firm conclusions based 
on these three studies. Study LYBV involved a different pattern 
of findings that could be explained by the study design. Unlike 
the other two studies, Study LYBV included only patients who 
were in paid employment, and measured work productivity as the 
primary outcome. Furthermore, there was a high drop-out rate in 
this study, potentially influencing the results, and overall a nega-
tive result for improvement in ADHD symptoms not consistent 
with the findings from the other adult ATX studies. Further evi-
dence for possible enhanced effects over longer periods of time 
comes from a separate long-term open-label follow-up study, 
which found that some individual patients who failed to respond 
during a randomized trial phase of the study responded at a later 
time point (Marchant et al., 2011). Overall, these findings sug-
gest that in most cases a significant response will be seen within 
four weeks, with further improvements in effect size expected up 
to 12 weeks.
To evaluate the generalizability of the result of the acute inte-
grated analysis, we performed subgroup analyses by age group, 
ethnicity, sex, CYP2D6 status, prior stimulant use, baseline 
ADHD severity, baseline quality-of-life, and ADHD subtype. 
These analyses did not show any clinically relevant differences in 
the efficacy of ATX for any of these subgroups, apart from small 
but statistically significant differences seen in the ethnicity anal-
yses. This should assure good generalizability of the efficacy data 
to clinical practice (Surman et al., 2010), although it does not 
take account of common comorbidities seen in adults with 
ADHD. Two of the studies suggest that ATX is effective in adult 
cases of ADHD with comorbid social anxiety and alcohol abuse 
disorders (Adler et al., 2009a; Wilens et al., 2011).
While both of these integrated analyses of ATX are solely 
based on the nine Eli Lilly-sponsored studies, for which complete 
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Table 4. Efficacy data (CAARS-INV: SV, CGI-ADHD-S, AAQoL scores) from the short-term and longer-term studies (integrated analyses).
Parameter Short-term studies integrated analysis Longer-term studies integrated analysis
Placebo ATX ATX vs placebo, 
p-value
Placebo ATX ATX vs placebo, 
p-value
CAARS-Inv: SV total score, n 863 849 557 663  
Baseline, mean±SD 35.2±8.1 35.0±8.2 35.6±8.2 34.8±8.2  
Endpoint, mean±SD 26.8±11.2 22.6±11.4 25.9±11.9 21.7±11.6  
Change to endpoint, mean±SD −8.4±10.0 −12.4±10.9 −9.7±11.8 −13.2±12.1  
ATX vs placebo, LS mean (95% CI) −4.1 (−5.0– −3.2) <0.001 −3.9 (−5.2– −2.7) <0.001
CAARS-Inv: SV, inattentive score, n 863 849 557 665  
Baseline, mean±SD 20.4±4.1 20.2±4.2 20.2±4.1 20.0±4.3  
Endpoint, mean±SD 15.6±6.3 13.3±6.5 14.9±6.9 12.6±6.7  
Change to endpoint, mean±SD −4.7±5.9 −6.9±6.3 −5.4±6.9 −7.5±7.0  
ATX vs placebo, LS mean (95% CI) −2.2 (−2.8– −1.7) <0.001 −2.2 (−2.9– −1.4) <0.001
CAARS-Inv: SV, hyperactive/ impulsive score, n 863 849 557 664  
Baseline, mean±SD 14.8±5.8 14.8±5.8 15.4±5.8 14.8±5.8  
Endpoint, mean±SD 11.2±6.3 9.3±6.1 11.1±16.2 9.1±5.9  
Change to endpoint, mean±SD −3.7±5.1 −5.5±5.5 −4.3±5.9 –5.7±6.1  
ATX vs placebo, LS mean (95% CI) −1.9 (−2.3– −1.4) <0.001 −1.7 (−2.3– −1.1) <0.001
CGI-ADHD-S score, n 652 640 611 758  
Baseline, mean±SD 4.7±0.7 4.8±0.7 4.6±0.6 4.6±0.7  
Endpoint, mean±SD 4.1±1.1 3.7±1.1 3.8±1.1 3.5±1.2  
Change to endpoint, mean±SD −0.6±1.0 −1.0±1.2 −0.8±1.1 –1.1±1.2  
ATX vs placebo, LS mean (95% CI) −0.4 (−0.5– −0.3) <0.001 −0.35 (−0.5– −0.2) <0.001
AAQoL total score, n 561 538 344 440  
Baseline, mean±SD 45.1±14.3 45.0±14.8 47.4±13.1 47.2±13.2  
Endpoint, mean±SD 54.8±16.4 58.7±17.9 57.0±17.3 60.7±17.2  
Change to endpoint, mean±SD 9.7±14.8 13.7±16.5 9.6±15.8 13.5±16.2  
ATX vs placebo, LS mean (95% CI) 4.0 (2.2–5.7) <0.001 3.6 (1.5–5.8) 0.001
AAQoL subscore for life productivity 
measurement, n
561 538 342 440  
Baseline, mean±SD 40.7±19.3 40.5±19.2 41.4±16.9 41.8±16.6  
Endpoint, mean±SD 52.4±21.3 57.2±22.7 53.8±21.0 58.9±20.6  
Change to endpoint, mean±SD 11.7±19.8 16.8±21.7 12.4±21.3 17.1±20.7  
ATX vs placebo, LS mean (95% CI) 4.9 (2.7–7.2) <0.001 4.5 (1.8–7.3) 0.001
AAQoL subscore for psychological health 
measurement, n
560 539 343 441  
Baseline, mean±SD 46.1±20.1 45.8±21.0 51.2±19.4 49.0±19.8  
Endpoint, mean±SD 56.0±21.0 59.5±22.6 59.3±21.5 61.4±21.2  
Change to endpoint, mean±SD 9.9±20.5 13.6±21.5 8.1±19.9 12.5±21.0  
ATX vs placebo, LS mean (95% CI) 3.7 (1.4–5.9) 0.001 3.1 (0.5–5.7) 0.021
AAQoL subscore for life outlook  
measurement, n
558 538 343 440  
Baseline, mean±SD 47.0±16.0 47.8±16.8 49.9±14.0 50.7±14.8  
Endpoint, mean±SD 53.2±17.8 56.4±19.3 56.4±17.5 60.3±17.6  
Change to endpoint, mean±SD 6.2±15.6 8.7±18.1 6.5±16.0 9.7±16.6  
ATX vs placebo, LS mean (95% CI) 2.8 (0.9–4.6) 0.003 3.3 (1.1–5.5) 0.003
AAQoL subscore for relationships 
measurement, n
561 539 343 440  
Baseline, mean±SD 51.1±20.8 50.6±20.7 <0.001 52.6±18.8 52.4±18.7 0.053
Endpoint, mean±SD 60.8±21.1 64.4±21.1 62.2±20.3 64.7±20.1  
Change to endpoint, mean±SD 9.7±20.3 13.8±21.1 9.5±19.5 12.3±19.7  
ATX vs placebo, LS mean (95% CI) 3.9 (1.7–6.0) 2.5 (0.0–5.0)  
AAQoL: Adult ADHD Quality-of-Life; ADHD: attention deficit hyperactivity disorder; ATX: atomoxetine; CAARS-Inv: SV: Conners’ Adult ADHD Rating Scale–Investigator-Rated; CGI-ADHD-S: Clinical 
Global Impressions of ADHD-Severity; CI: confidence interval (two-sided); LS: least square; n: number of randomized patients with baseline and post-baseline result(s).
Studies LYBY and LYDQ are excluded from CGI-ADHD-S descriptive statistics because they were conducted in comorbid populations. Similarly, Study LYBY did not collect CAARS-Inv: SV data, and Studies 
LYAA, LYAO and LYBY did not collect AAQoL data, p-values for mean CGI-ADHD-S, CAARS-Inv: SV and AAQoL scores are from the Type III sums of squares analysis of variance (ANOVA) model: change: 
treatment + study + baseline value; p-values for response rates are from the Cochran Mantel-Haenszel method.
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individual data are available, it is notable that the efficacy of ATX 
has also been investigated in five controlled studies that were 
not sponsored by Eli Lilly (Bain et al., 2013; McRae-Clark 
et al., 2010; Sobanski et al., 2012, 2013; Sutherland et al., 
2012; Weisler et al., 2012). We did not include these non-Eli 
Lilly-sponsored studies in the current analyses because indi-
vidual data of these were not available. In addition, the design 
of these studies was difficult to compare (e.g. crossover; Bain 
et al., 2013), they were not completely blinded or not placebo-
controlled (Sobanski et al., 2012, 2013), or had a very high 
drop-out rate (McRae-Clark et al., 2010).  Nevertheless, ATX 
was shown to be effective in all five of these placebo-controlled 
studies. For example in the first period of the crossover study 
by Bain et al. (2013), the effect size for ATX vs placebo was 
0.57.
Conclusions
In summary, these data show that ATX has a statistically signifi-
cant and clinically relevant response in adults with ADHD, which 
is maintained over six months. Indirect comparison of the results 
of these integrated analyses of ATX studies with those from stud-
ies of stimulants in adults with ADHD suggests that the effect 
size may be more similar than previously thought. Not all adult 
patients are likely to respond or are able to tolerate stimulants, 
and there are additional advantages of ATX in some cases. The 
low abuse and diversion potential of ATX, possibility of once or 
twice daily dosing with enduring efficacy, stable effect through-
out the day, and demonstrated effectiveness in reducing ADHD 
symptoms in patients with comorbid social anxiety and alcohol 
use disorders, make ATX an important medication to consider 
when treating adult patients with ADHD.
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